|
Basic Characteristics of Mutations
|
|
Mutation Site
|
M460I |
|
Mutation Site Sentence
|
One patient has a resistance-related mutation (M460I); the major risk factor for emergence of resistance in this patient was the presence of early and persistent antigenaemia. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL97 |
|
Standardized Encoding Gene
|
UL97
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
AD169;Towne
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HCMV Antigenaemia
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
ganciclovir |
|
Location
|
French |
|
Literature Information
|
|
PMID
|
15221901
|
|
Title
|
Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection
|
|
Author
|
Alain S,Hantz S,Scieux C,Karras A,Mazeron MC,Szelag JC,Imbert BM,Fillet AM,Gouarin S,Mengelle C,De Wilde A,Cogne N,Champier G,Rogez S,Legendre C,Denis F
|
|
Journal
|
Journal of medical virology
|
|
Journal Info
|
2004 Aug;73(4):566-73
|
|
Abstract
|
Whether valaciclovir (VCV) prophylaxis could be responsible for ganciclovir (GCV)-resistance of Human cytomegalovirus (HCMV) in transplantation has never been documented. A multicentric retrospective pilot study was undertaken to detect GCV-resistance through mutations within the UL97 gene in renal transplant recipients who experienced active HCMV infection and received valacyclovir prophylaxis. Twenty-three patients who experienced HCMV antigenaemia or DNAemia during or at the end of prophylaxis were included. UL97 genotyping was carried out on peripheral blood samples, using a nested in-house PCR, which amplified the full-length UL97 gene. One patient has a resistance-related mutation (M460I); the major risk factor for emergence of resistance in this patient was the presence of early and persistent antigenaemia. GCV-resistance during VCV-prophylaxis was rare after renal transplantation. However, special attention must be paid to patients developing early active HCMV infection under prophylaxis.
|
|
Sequence Data
|
-
|